FLT3 and acute myeloid leukemia: In one data point, therapeutic schedules of different dosing midostaurin combined with chemotherapy in 69 AML patients younger than 60 years with FLT3 mutation or FLT-WT showed CR rates, 80% in a twice daily 50 mg dose cohort (n = 40) [43].